The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Cancer Research and Treatment - South Korea
doi 10.4143/crt.2017.512
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Cancer Association

Related search

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors

Tumor Biology
MedicineCancer Research
2017English

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of Cancer
Oncology
2018English

Pseudoprogression and Rapid Response to Pembrolizumab in a Patient With Advanced Lung Adenocarcinoma With Loss of Epidermal Growth Factor Receptor Gene Mutation After Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

Polo-Like Kinase 1 Inhibition Diminishes Acquired Resistance to Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer With T790M Mutations

Oncotarget
Oncology
2016English

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

Oncology Letters
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy